Integrating Both Parallax and Latency Compensation into Video See-through Head-mounted Display.

This work introduces a perspective-corrected video see-through mixed-reality head-mounted display with edge-preserving occlusion and low-latency capabilities. To realize the consistent spatial and temporal composition of a captured real world containing virtual objects, we perform three essential tasks: 1) to reconstruct captured images so as to match the user's view; 2) to occlude virtual objects with nearer real objects, to provide users with correct depth cues; and 3) to reproject the virtual and captured scenes to be matched and to keep up with users' head motions. Captured image reconstruction and occlusion-mask generation require dense and accurate depth maps. However, estimating these maps is computationally difficult, which results in longer latencies. To obtain an acceptable balance between spatial consistency and low latency, we rapidly generated depth maps by focusing on edge smoothness and disocclusion (instead of fully accurate maps), to shorten the processing time. Our algorithm refines edges via a hybrid method involving infrared masks and color-guided filters, and it fills disocclusions using temporally cached depth maps. Our system combines these algorithms in a two-phase temporal warping architecture based upon synchronized camera pairs and displays. The first phase of warping is to reduce registration errors between the virtual and captured scenes. The second is to present virtual and captured scenes that correspond with the user's head motion. We implemented these methods on our wearable prototype and performed end-to-end measurements of its accuracy and latency. We achieved an acceptable latency due to head motion (less than 4 ms) and spatial accuracy (less than 0.1° in size and less than 0.3° in position) in our test environment. We anticipate that this work will help improve the realism of mixed reality systems.

[Effectiveness of Allergy Regimen for Allergic Reactions to Oxaliplatin].

Oxaliplatin, a platinum-containing antineoplastic agent, is a key drug for the treatment of colorectal cancer and gastric cancer; however, some patients develop allergic reactions. Our hospital uses a regimen to control allergic reactions in patients with mild allergies(Grade 1 and 2). The aim of this study was to determine the effectiveness and safety of our allergy regimen. We retrospectively investigated 22 patients who initiated our allergy regimen between January 2017 and December 2017. The median number of administration cycles before allergy development was 8, and the median cumulative dose of oxaliplatin was 700mg/m2. Of the 22 patients, 18(82%)were able to continue oxaliplatin therapy. Drowsiness was the only adverse event that occurred in this cohort. Our allergy regimen may be effective for controlling allergic reactions to oxaliplatin in patients with mild allergies.

[Case report of atropine poisoning, after accidental ingestion of 500mg atropine sulfate].

A case report of atropine intoxication, after the accidental ingestion of 500mg atropine sulfate is presented. The patient was a 58 year old male. Atropine sulfate 0.5mg p.o. was prescribed but inadvertently 500mg was dispensed by the pharmacy. Within 1 hour of ingestion, the patient became unconscious and was admitted to Saint Luke's International Hospital. Unresponsive to verbal and tactile stimuli with a significant decrease in response to painful stimuli, respiratory suppression, and mydriasis were evident. The serum concentration of atropine at the time of admission (4 hour after ingestion) was 244 ng/mL. He was treated in our ICU and placed under sedation utilizing in a Propofol and Fentanyl intravenously. Ventilator control, ECG monitoring and intravenous fluid support was provided. Three days after admission, the patient's level of consciousness improved. After 5 days, he was transferred to a general ward. Upon discharge, only mild diplopia remained as a sequela of the intoxication. The patient was followed in the outpatient department and his health returned to pre-ingestion level. Clinically, the diagnosis of atropine intoxication is difficult to make. If information regarding atropine ingestion is not readily available, adequate respiratory support, circulatory monitoring and proper symptomatic treatment are necessary to ensure recovery.